Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer

PURPOSE: Although gemcitabine plus cisplatin has been established as the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC), overall prognosis remains poor. We investigated the efficacy of a novel triplet combination of oxaliplatin, irinotecan, and S-1 (OIS) for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Han, Boram, Kim, Hyeong Su, Kim, Kyu-pyo, Kim, Deokhoon, Jeong, Jae Ho, Lee, Jae-Lyun, Kim, Tae Won, Kim, Jung Han, Choi, Dae Ro, Ha, Hong Il, Seo, Jinwon, Chang, Heung-Moon, Ryoo, Baek-Yeol, Zang, Dae Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192931/
https://www.ncbi.nlm.nih.gov/pubmed/29334603
http://dx.doi.org/10.4143/crt.2017.526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192931/
https://www.ncbi.nlm.nih.gov/pubmed/29334603
http://dx.doi.org/10.4143/crt.2017.526

Ejemplares similares